Austin, TX (PRWEB) April 26, 2013
Altogen Labs, a biotechnology company focused on providing biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide, today announced addition of new pre-clinical contract research services enabling companies to accelerate pre-clinical research needs.
Pre-clinical trials assess the toxicity and pharmacological activity of investigative new drugs (INDs) to assess a compound’s therapeutic potential and safety for human use. A very important component of pre-clinical trials includes in vivo toxicology analysis. At Altogen Labs, in vivo toxicology studies can include acute, subchronic, and chronic toxicity tests to study of toxic effects of chemical substances.
Altogen Labs provides following in vivo services for efficacy studies in the drug discovery phase: rodent xenograft models, teratoma formation and analysis services, cancer disease animal models, in vivo siRNA delivery and tissue targeting, pharmacokinetics (PK) and pharmacodynamics (PD) services, immune response and biomarker analysis.
To accelerate the development of new anti-cancer medicines, Altogen Labs offers in vivo xenograft services for drug development studies to treat inflammation, infectious diseases, cancer, pain, immunology and obesity. As a GLP-compliant laboratory, animal handling is IACUC-regulated and in accordance with FDA regulations. A variety of disease models are now available for testing.
Altogen Labs excels in providing excellent preservation and maintenance of cel
Copyright©2012 Vocus, Inc.
All rights reserved